Key takeaways: Patients who received 4D-150 3E10 vg/eye experienced an 8.4 letter increase in BCVA. 4DMT is progressing to a phase 3 trial for 4D-150 3E10 vg/eye.

This designation in DME follows the RMAT designation granted for 4D-150 in wet AMD, and to our knowledge, 4D-150 is the first investigational medicine to be granted the designation in both ...

Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.“Duravyu ...